



Docket No: GI5388 CH  
Patent

16/4  
RECEIVED  
AUG 01 2003  
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re of Application of: JACOBS, et al  
Application No.: 10/084,298 Group Art No.: 1614  
Filed: February 25, 2002 Examiner:  
For: COMPOSITION AND METHOD FOR TREATING  
INFLAMMATORY DISORDERS  
Confirmation No.: 7985  
Customer Number: 25291

Assistant Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

1. Preliminary Statements

In accordance with 37 CFR 1.97 and 1.98, Applicants submit herewith patents, publications, or other information of which they are aware. References 5-10 were cited on an International Search Report issued in a corresponding PCT application (PCT/US02/05684). A copy of the International Search Report dated June 30, 2003 is enclosed. References 1-4 and 8-10 are newly cited.

This Information Disclosure Statement is not to be construed as a representation that: (i) a search has been made; (ii) the information is material to the examination of this application; (iii) additional information material to the examination of this application does not exist; (iv) the information, protocols, results and the like reported by third parties are accurate or enabling; or (v) the information constitutes prior art to the subject invention.

**CERTIFICATE OF MAILING 37 CFR §1.10**

I hereby certify that this paper and the documents referred to as enclosed therein are being deposited with the United States Postal Service on the date written below in an envelope as "Express Mail Post Office to Addressee" Mailing Label Number EV 239490566 US addressed to the Assistant Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450.

7/30/03  
Date

Kerry A. Ovidio  
Kerry A. Ovidio

2. Identification of Time of Filing

This Information Disclosure Statement

- a. ☐ is filed within three months of the filing date of the application.
- b. ☒ is filed before the mailing date of a first Office Action on the merits.
- c. ☐ is filed before the mailing date of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.
- d. ☐ is filed after the period specified in 2(a), 2(b) or 2(c) above, but before the mailing date of a final action under 37 CFR 1.311. This statement includes a certification under 37 CFR 1.97(e) or the fee set forth in 37 CFR 1.17(p).
- e. ☐ is filed after the mailing date of a final action or Notice of Allowance but before payment of the issue fee. This statement includes (i) a certification under 37 CFR 1.97(e), and (ii) the fee set forth in 37 CFR 1.17(p).

3. ☐ Certification under 37 CFR 1.97(e) and 1.704(d)

The undersigned attorney certifies

- a. ☐ that each item of information contained in the Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the statement, or
- b. ☐ that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the statement.
- c. ☐ The undersigned attorney certifies that each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign application patent office in a counterpart foreign application and was not received by any individual designated in 37 CFR 1.56(c) more than thirty (30) days prior to the filing of the statement.

☒ Newly Cited Information

A legible copy of references 1-4 and 8-10 cited on the attached form PTO 1449 is enclosed. References 5-7 were previously submitted on the Information Disclosure Statement filed in the above-referenced application on October 28, 2002, and thus no copy is enclosed.

☒ Previously Cited Information

No copy of the patents, publications or other information cited on the attached form PTO-1449 is enclosed because it has been previously cited by or submitted to the Office on the Information Disclosure Statement filed in the above-referenced application on October 28, 2002.

- ☐ Concise Explanation  
Documents cited above which are not in the English Language
- a. ☐ have been explained in the specification.
- b. ☐ have an abstract (or other concise explanation) in English enclosed or if readily available a translation into English of the document is enclosed.

Form PTO-1449 is enclosed in duplicate.

- ☐ Fees  
☐ Fee for filing under 37 CFR 1.97(c) or (d) Fee: \$180.00

Method of Payment of Fees:

Charge Deposit Account No. 07-1060 in the amount of \$0.00

A duplicate of this statement is enclosed.

Instructions as to Overpayment/Underpayment:

Credit any overpayment and charge any underpayment to Deposit Account No. 07-1060.



Diana M. Collazo

Reg. No. 46,635

Wyeth  
Patent Law Department  
Five Giralda Farms  
Madison, NJ 07940  
Tel. No. (617) 665-8775

S:\LACOMMONPATENTS\AMEND\5358\CIP\Supp IDS 07-24-03.doc

Substitute for form 1449/PTO			Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Application Number	10/084,298
			Filing Date	February 25, 2002
			Applicant	JACOBS, et al
			Group Art Unit	1614
			Examiner Name	
Sheet	1	of	Attorney Docket Number	GI5358 CIP

### U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number (If known)	Kind Code (If Known)			
	1.	2002/0102723		Gurney, A., et al	08-01-2002	
	2.	2002/0187523		Tang, Y., et al	12-12-2002	
	3.	2002/0012669		Presnell, S., et al	01-31-2002	
	4.	6,551,799		Gurney, A., et al	04-22-2003	

### FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (If Known)				

### OTHER PRIOR ART — NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	5.	Dumoutier, L. et al: "Cloning and Characterization of IL-10-Related T Cell-Derived Inducible Factor (IL-TIF), A Novel Cytokine Structurally Related to IL-10 and Inducible By IL-9" Journal of Immunology, Blackwell Scientific Publications, GB, vol. 164, 2000, pages 1814-1819	<input type="checkbox"/>
	6.	Dumoutier, L. et al: "Human Interleukin-10-Related T Cell-Derived Inducible Factor: Molecular Cloning and Functional Characterization as an Hepatocyte-Stimulating Factor" Proceedings of the National Academy of Sciences of USA, National Academy of Science. Washington, US, vol. 97, no. 18, 29 August 2000, pages 10144-10149	
	7.	Xie, M-H et al: "Interleukin (IL)-22, a novel human cytokine that signals through the interferon receptor-related proteins CRF2-4 and IL-22R" Journal of Biological Chemistry, American Society of Biological Chemists, Baltimore, MD, US, vol. 275, no. 40, 6 October 2000, pages 31335-31339	
	8.	Kotenko, Sergei V. et al: "Identification of the functional interleukin-22 (IL-22) receptor complex. The IL-10R2 chain (IL-10Rbeta) is a common chain of both the IL-10 and IL-22 (IL-10-related T cell-derived inducible factor, IL-TIF) receptor complexes" Journal of Biological Chemistry, American Society of Biological Chemists, Baltimore, MD, US, vol. 276, no. 4, 26 January 2001, pages 2725-2732	
	9.	Dumoutier, L. et al: "IL-TIF induces acute phase reactant production by hepatocytes through IL-10Rbeta." Immunology Letters, vol. 73, no. 2-3 September 2000, page 261	
	10.	Lambert, A. et al: "Novel cytokine IL-22 administrated by adenovirus vector or as recombinant purified protein induces acute-phase responses and renal tubular basophilia in female C57BL/6 mice." Toxicologic Pathology, vol. 29, no. 6, November 2001, page 712	

S:\LACOMMON\PATENTS\AMENDS\5358\CIP\PTO 1449 07-24-03.doc

Examiner Signature	Date Considered
-----------------------	--------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.